A carregar...
Profile of bevacizumab in the treatment of platinum-resistant ovarian cancer: current perspectives
Patients with platinum-resistant ovarian cancer have progression of disease within 6 months of completing platinum-based chemotherapy. While several chemotherapeutic options exist for the treatment of platinum-resistant ovarian cancer, the overall response to any of these therapies is ~10%, with a m...
Na minha lista:
| Publicado no: | Int J Womens Health |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4803258/ https://ncbi.nlm.nih.gov/pubmed/27051317 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/IJWH.S78101 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|